NCT06349577

Brief Summary

The objective is to determine the effectiveness of pulsatile flow during cardiopulmonary bypass to reduce the incidence of acute kidney injury after cardiac surgery. Investigators will also evaluate the safety and impact of pulsatile flow on clinical outcomes compared to non-pulsatile flow during cardiopulmonary bypass.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,100

participants targeted

Target at P75+ for not_applicable

Timeline
29mo left

Started May 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress29%
May 2025Oct 2028

First Submitted

Initial submission to the registry

March 19, 2024

Completed
17 days until next milestone

First Posted

Study publicly available on registry

April 5, 2024

Completed
1.1 years until next milestone

Study Start

First participant enrolled

May 19, 2025

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2028

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2028

Last Updated

May 21, 2025

Status Verified

May 1, 2025

Enrollment Period

2.9 years

First QC Date

March 19, 2024

Last Update Submit

May 19, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Acute kidney injury

    Stage 1 (mild), 2 (moderate), or 3 (severe) acute kidney injury according to the Kidney Disease Improving Global Outcomes creatinine criteria (stage 1 = 1.5 to 1.9 times baseline or greater than or equal to 0.3 milligrams per deciliter increase in serum creatinine, stage 2 = 2.0 to 2.9 times baseline in serum creatinine, stage 3 = 3.0 times baseline or increase in serum creatinine greater than or equal to 4.0 milligrams per deciliter or initiation of renal replacement therapy

    From intensive care unit admission after surgery up to 7 days

Secondary Outcomes (5)

  • Acute kidney injury risk score

    On admission to the intensive care unit after surgery up to 24 hours after intensive care unit arrival

  • Red blood cell units transfused

    After cardiopulmonary bypass up to 24 hours after intensive care unit arrival

  • Platelet nadir

    On admission to the intensive care unit after surgery up to 7 days

  • Discontinuation rate of cardiopulmonary bypass mode

    During cardiopulmonary bypass

  • 30-day mortality

    From intensive care unit admission after surgery to hospital discharge, up to 30 days

Other Outcomes (21)

  • Myocardial infarction

    From intensive care unit admission after surgery to hospital discharge, up to 30 days

  • Stroke

    From intensive care unit admission after surgery to hospital discharge, up to 30 days

  • Renal failure requiring renal replacement therapy

    From intensive care unit admission after surgery to hospital discharge, up to 30 days

  • +18 more other outcomes

Study Arms (2)

Non-pulsatile blood flow

ACTIVE COMPARATOR

Non-pulsatile blood flow during cardiopulmonary bypass

Other: Non-pulsatile blood flow

Pulsatile blood flow

ACTIVE COMPARATOR

Pulsatile blood flow during cardiopulmonary bypass

Other: Pulsatile blood flow

Interventions

Non-pulsatile blood flow generated by constant centrifugal pump flow rate during cardiopulmonary bypass

Non-pulsatile blood flow

Pulsatile blood flow generated by variable centrifugal pump flow rate during cardiopulmonary bypass

Pulsatile blood flow

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Able to provide informed consent
  • Scheduled for elective cardiac surgery with cardiopulmonary bypass

You may not qualify if:

  • Emergency procedures
  • Scheduled for heart or lung transplantation
  • Scheduled for ventricular assist device implantation
  • Use of the Medtronic Elongated Once-Piece Arterial Cannula
  • Diagnosed with sepsis
  • Diagnosed with delirium
  • Experiencing hemodynamic instability (heart rate \> 100 and systolic blood pressure \< 90)
  • Requiring mechanical circulatory support
  • Requiring vasoactive medications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Colorado Hospital

Aurora, Colorado, 80045, United States

RECRUITING

Related Publications (3)

  • Demirjian S, Bashour CA, Shaw A, Schold JD, Simon J, Anthony D, Soltesz E, Gadegbeku CA. Predictive Accuracy of a Perioperative Laboratory Test-Based Prediction Model for Moderate to Severe Acute Kidney Injury After Cardiac Surgery. JAMA. 2022 Mar 8;327(10):956-964. doi: 10.1001/jama.2022.1751.

    PMID: 35258532BACKGROUND
  • Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-84. doi: 10.1159/000339789. Epub 2012 Aug 7. No abstract available.

    PMID: 22890468BACKGROUND
  • Tan A, Newey C, Falter F. Pulsatile Perfusion during Cardiopulmonary Bypass: A Literature Review. J Extra Corpor Technol. 2022 Mar;54(1):50-60. doi: 10.1182/ject-50-60.

    PMID: 36380831BACKGROUND

MeSH Terms

Conditions

Acute Kidney InjuryHemolysisThrombocytopenia

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsBlood Platelet DisordersHematologic DiseasesHemic and Lymphatic DiseasesCytopenia

Study Officials

  • Nathan J Clendenen, MD, MS

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nathan J Clendenen, MD,MS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 19, 2024

First Posted

April 5, 2024

Study Start

May 19, 2025

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

October 1, 2028

Last Updated

May 21, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations